In an adult with personal or family history of premature cardiovascular disease or unexplained high LDL‑cholesterol, when should lipoprotein(a) be measured and what are the recommended management steps for elevated lipoprotein(a) levels?

Lipoprotein(a) Measurement and Management

Measure lipoprotein(a) at least once in all adults, particularly those with personal or family history of premature cardiovascular disease, familial hypercholesterolemia, unexplained high LDL-cholesterol, or recurrent cardiovascular events despite optimal therapy 1, 2.

When to Measure Lp(a)

The 2026 ACC/AHA multisociety guideline recommends universal screening with Lp(a) measurement at least once in lifetime for all adults 3, 1, 2. This represents a significant shift toward broader testing compared to earlier selective approaches.

Priority populations for testing include:

• Adults with premature ASCVD (men <55 years, women <65 years)
• Family history of premature cardiovascular disease or elevated Lp(a)
• Familial hypercholesterolemia
• Recurrent cardiovascular events despite optimal lipid-lowering therapy
• Unexplained high LDL-cholesterol levels
• Individuals of African or South Asian ancestry (higher prevalence of elevated Lp(a)) 4, 5, 6

Cascade testing is recommended for family members when an individual is found to have very high Lp(a) levels (>50 mg/dL or >125 nmol/L), given the genetic determination of Lp(a) levels 7, 5.

Key Testing Considerations

• Single lifetime measurement is sufficient because Lp(a) levels are genetically determined, reach peak by age 5, and remain stable throughout life 7, 6
• Elevated Lp(a) is defined as >30 mg/dL (>75 nmol/L) for risk assessment, though very high levels >50 mg/dL (>125 nmol/L) confer substantially greater risk 4, 5, 8
• Approximately 20-25% of the general population has elevated Lp(a), with higher prevalence in certain ethnic groups 7, 8

Management of Elevated Lp(a)

Risk Stratification and Treatment Targets

Use elevated Lp(a) as a risk enhancer to guide more aggressive management of traditional cardiovascular risk factors 9, 5. The 2026 guideline reintroduces specific LDL-C, non-HDL-C, and apoB treatment goals based on risk category 3, 1.

When Lp(a) is elevated, cardiovascular event rates remain higher at any achieved LDL-C level, indicating unaddressed Lp(a)-mediated residual risk 4, 8. This justifies lower LDL-C treatment goals in these patients.

Current Therapeutic Approach

The cornerstone of management is aggressive control of modifiable cardiovascular risk factors, with particular emphasis on intensive LDL-cholesterol lowering 9, 10, 5.

Specific Interventions:

1. Statin Therapy

• Initiate or intensify statin therapy to achieve lower LDL-C targets
• Note: Statins have neutral or potentially detrimental effects on Lp(a) levels themselves, but remain essential for LDL-C reduction 8, 6

2. PCSK9 Inhibitors

• Strongly consider PCSK9 inhibitors (evolocumab, alirocumab) or inclisiran in patients with elevated Lp(a) and high cardiovascular risk
• These agents reduce Lp(a) by approximately 25-30% in addition to substantial LDL-C lowering 9, 7, 8
• This represents the most effective currently available therapy for Lp(a) reduction

3. Antiplatelet Therapy

• Consider aspirin for primary prevention in select patients with very high Lp(a) and additional risk factors 9
• Prolonged dual antiplatelet therapy may be beneficial in secondary prevention for patients with elevated Lp(a) and established ASCVD 9

4. Comprehensive Risk Factor Management

• Aggressive blood pressure control
• Diabetes management with optimal glycemic control
• Smoking cessation
• Weight management and regular physical activity
• Treatment of hypertriglyceridemia if present 5, 6

Advanced Therapies

Lipoprotein apheresis is an option for patients with very high Lp(a) (typically >60 mg/dL) and progressive cardiovascular disease despite optimal medical management 5, 8. This therapy can reduce Lp(a) by 60-75% acutely, though levels rebound between treatments.

Emerging Targeted Therapies

Antisense oligonucleotides (pelacarsen) and siRNA agents (olpasiran) are under investigation in phase 3 cardiovascular outcomes trials, demonstrating Lp(a) reductions of 80-90% 7, 10, 8, 6. The Lp(a)HORIZON trial will determine whether specific Lp(a) lowering reduces cardiovascular events 8.

Clinical Algorithm

1. Identify high-risk patients using criteria above and measure Lp(a) once
2. If Lp(a) >30 mg/dL: Use as risk enhancer, calculate 10-year ASCVD risk with PREVENT score, consider coronary calcium scoring 3, 1
3. If Lp(a) >50 mg/dL: Pursue aggressive risk factor modification with lower LDL-C targets
4. Initiate high-intensity statin unless contraindicated
5. Add PCSK9 inhibitor if LDL-C remains elevated or patient has established ASCVD
6. Consider aspirin for primary prevention in very high-risk patients
7. Screen family members (cascade testing) when Lp(a) >50 mg/dL
8. Refer for lipoprotein apheresis if Lp(a) >60 mg/dL with progressive disease despite optimal therapy

Critical Pitfalls to Avoid

• Do not delay testing due to uncertainty about management—elevated Lp(a) is actionable today with current therapies 9
• Do not rely on statins alone for patients with elevated Lp(a) and high cardiovascular risk—consider PCSK9 inhibitors early 6
• Do not ignore family screening—Lp(a) is genetically determined with 90% heritability 5
• Do not repeat Lp(a) testing routinely—levels remain stable throughout life unless specific clinical situations arise (thyroid disease, chronic kidney disease, acute inflammation) 7, 6